See more : Globe Commercials Limited (GLCL.BO) Income Statement Analysis – Financial Results
Complete financial analysis of INmune Bio, Inc. (INMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INmune Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- PeakBirch Commerce Inc. (PKBFF) Income Statement Analysis – Financial Results
- Qingdao Gaoce Technology Co., Ltd (688556.SS) Income Statement Analysis – Financial Results
- Well Graded Engineering Public Company Limited (WGE.BK) Income Statement Analysis – Financial Results
- Tatatu S.p.A. (ALTTU.PA) Income Statement Analysis – Financial Results
- Acomo N.V. (ACNFF) Income Statement Analysis – Financial Results
INmune Bio, Inc. (INMB)
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.27M | 17.07M | 20.54M | 5.92M | 3.28M | 1.11M | 435.36K | 101.50K | 0.00 |
| General & Administrative | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 195.47K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -146.60K |
| SG&A | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 48.87K |
| Other Expenses | 0.00 | -1.35M | -1.19M | 128.52K | 0.00 | 0.00 | -6.00 | 0.00 | 0.00 |
| Operating Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Cost & Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 77.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 29.74M | 25.95M | 29.15M | 12.23M | 9.30M | 12.44M | 981.48K | 227.49K | 195.47K |
| EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 149.99K | -50.00K | 146.60K |
| EBITDA Ratio | 0.00% | -6,938.77% | -16,106.63% | -112,016.09% | -13.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.74M | -25.95M | -29.15M | -12.23M | -7.76M | -12.44M | -981.48K | -227.49K | -48.87K |
| Operating Income Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -9.98% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -267.00K | -1.35M | -1.19M | 129.00K | 77.69K | 0.00 | 149.99K | -50.00K | 0.00 |
| Income Before Tax | -30.01M | -27.30M | -30.34M | -12.10M | -7.68M | -12.44M | -831.49K | -277.49K | -48.87K |
| Income Before Tax Ratio | -19,360.00% | -7,299.20% | -16,762.43% | -110,838.76% | -9.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.35M | -29.15M | -12.23M | 1.46M | -161.14K | -1.13M | -177.49K | 0.00 |
| Net Income | -30.01M | -28.65M | -30.34M | -12.10M | -9.14M | -12.44M | -831.49K | -277.49K | -48.87K |
| Net Income Ratio | -19,360.00% | -7,659.63% | -16,762.43% | -110,838.76% | -11.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| EPS Diluted | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
| Weighted Avg Shares Out (Dil) | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
INmune Bio, Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on Thursday, May 5
Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day
INmune (INMB) Begins Dosing in Mid-Stage Study With AD Candidate
INmune (INMB) doses the first patient in a phase II study with its investigational TNF inhibitor to treat Alzheimer's disease. Stock rises more than 12% post this announcement.
INmune Bio, Inc. to Present Preclinical Data on INB03 at the American Association for Cancer Research (AACR) Annual Meeting 2022
Data from animal models of trastuzumab-resistant MUC4 HER2+ breast cancer show that treatment with INB03 decreases MUC4 expression, reverses resistance to trastuzumab and tyrosine kinase inhibitors, and promotes an immunologically active tumor micro-environment
INmune Bio: Speculative Biotech With 2 Solid Potential Approaches To Treating AD And Solid Tumors
INKmune therapy, NK cell therapy, was shown to activate NK cells that killed off >70% of NK resistant tumor cells in an in vitro assay in an MDS patient.
INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call Transcript
INmune Bio, Inc. (INMB) CEO Raymond J. Tesi on Q4 2021 Results - Earnings Call Transcript
INmune Bio, Inc. to Report Fourth Quarter 2021 Financial Results and Provide a Corporate Update on Thursday, March 3
Management to host conference call and webcast at 4:30 pm ET on that day
INmune Bio, Inc. to Present at the BIO CEO & Investor Conference
BOCA RATON, Florida., Feb. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD,...
INmune Bio, The Biotech In My Stable For After Cassava Sciences
Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.
INmune Bio, Inc. to Participate in January Investor Conferences and a Medical Meeting
Boca Raton, Florida, Jan. 04, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that management will participate in...
INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call Transcript
INmune Bio, Inc. (INMB) CEO R. J. Tesi on Q3 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports